Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–380 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Familial Atypical Mole-Malignant Melanoma Syndrome Clear all
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 23, 2026, 1:45 PM EDT
Recruiting No phase listed Observational

Pancreas Registry and High Risk Registry

NCT02775461
View directory record Official record
Conditions
Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 23, 2026, 1:45 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

NCT06545682
View directory record Official record
Conditions
Melanoma (Skin Cancer), Breast Cancer, Brain Metastasases
Interventions
Alpelisib + Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

NCT00004148
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant vaccinia-B7.1 vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 1:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

NCT03693378
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
Interventions
Not listed
Lead sponsor
Immunovia, Inc.
Industry
Eligibility
Not listed
Enrollment
1,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
13
States / cities
Stanford, California • New Haven, Connecticut • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

NCT03028948
View directory record Official record
Conditions
Stage 0 Skin Melanoma, Stage I Skin Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage II Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage III Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
Internet-Based Intervention, Questionnaire Administration, Survey Administration
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005633
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
OVA BiP peptide, gp209-2M antigen, recombinant 70-kD heat-shock protein, tyrosinase peptide
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 23, 2026, 1:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

NCT07201376
View directory record Official record
Conditions
Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions
Ameluz 10% Topical Gel, Protoporphyrin IX
Drug · Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 1:45 PM EDT
Recruiting No phase listed Observational

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

NCT07327489
View directory record Official record
Conditions
Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
Interventions
Biopsy
Procedure
Lead sponsor
Elephas
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2038
U.S. locations
8
States / cities
Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 1:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control

NCT00295906
View directory record Official record
Conditions
Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions
educational intervention, internet-based intervention
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
4,550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
5
States / cities
San Diego, California • Wichita, Kansas • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

NCT00091143
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Providence Cancer Center, Earle A. Chiles Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 23, 2026, 1:45 PM EDT
Not listed Phase 1Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

NCT00004025
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 23, 2026, 1:45 PM EDT
Terminated Phase 1 Interventional

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

NCT04348916
View directory record Official record
Conditions
Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
Interventions
ONCR-177, pembrolizumab
Biological
Lead sponsor
Oncorus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Metastatic Melanoma

NCT00022464
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
temsirolimus
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 23, 2026, 1:45 PM EDT
Completed No phase listed Observational

Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)

NCT03535077
View directory record Official record
Conditions
Skin Lesion, Melanoma (Skin), Mole
Interventions
Diagnostic Test
Other
Lead sponsor
Orlucent, Inc
Industry
Eligibility
21 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Fremont, California • Irvine, California • Menlo Park, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 23, 2026, 1:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)

NCT00346502
View directory record Official record
Conditions
Dysplastic Nevus Syndrome
Interventions
20% betulinic acid ointment, BA
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer

NCT03294330
View directory record Official record
Conditions
Sentinel Lymph Node, Melanoma (Skin), Breast Cancer
Interventions
IC-Green KIT
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Poughkeepsie, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 23, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

NCT00005815
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 23, 2026, 1:45 PM EDT